证券代码:002693 证券简称: *ST双成 公告编号：2025-063 海南双成药业股份有限公司 第五届董事会第二十二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 海南双成药业股份有限公司（以下简称"公司"）第五届董事会第二十二次 会议通知于 2025 年 9 月 17 日以书面送达或电子邮件等方式发出，并于 2025 年 9 月 19 日以现场结合通讯表决的方式召开。会议应出席董事 6 人，实际参加表 决的董事 6 人。本次会议由董事长王成栋先生主持，会议的召开符合有关法律法 规、公司章程的规定。 二、董事会会议审议情况 根据《上市公司股权激励管理办法》《2025 年限制性股票与股票期权激励计 划（草案）》的相关规定以及公司 2025 年第二次临时股东会的授权，董事会认为 2025 年限制性股票与股票期权激励计划规定的授予条件已成就，同意以 2025 年 9 月 19 日为限制性股票与股票期权的授予日，向符合授予条件的 18 名激励对象 授予 1,200 万股限制性股票,向符合授予条件的 131 名激励对象授予 ...

证券代码：002693 证券简称：*ST双成 公告编号：2025-060 海南双成药业股份有限公司 董事会薪酬与考核委员会关于 2025 年限制性股票与股票期权 激励计划激励对象名单的审核意见及公示情况说明 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 海南双成药业股份有限公司（以下简称"公司"）于 2025 年 9 月 1 日召开第 五届董事会第二十一次会议，审议通过《关于<2025 年限制性股票与股票期权激励 计划（草案）>及其摘要的议案》等议案。根据《上市公司股权激励管理办法》 （以下简称"《管理办法》"）等相关规定，公司对 2025 年限制性股票与股票期 权激励计划（以下简称"本次激励计划"）拟激励对象的姓名和职务在公司内部进 行了公示，公司董事会薪酬与考核委员会结合公示情况对拟激励对象进行了核查， 相关公示情况及核查方式如下： 一、公示情况及核查方式 1、公司对拟激励对象的公示情况 公司于 2025 年 9 月 2 日在巨潮资讯网上披露了《2025 年限制性股票与股票期 权激励计划（草案）》及其摘要（以下简称"《激励计划（草案）》"）、《2025 ...

海南双成药业股份有限公司（以下简称"公司"）于 2025 年 9 月 1 日召开 第五届董事会第二十一次会议，审议通过《关于<2025 年限制性股票与股票期权 激励计划（草案）>及其摘要的议案》等议案，具体内容详见公司于 2025 年 9 月 2日刊登在《中国证券报》《证券时报》和巨潮资讯网(http://www.cninfo.com.cn/) 的相关公告。 公司针对 2025 年限制性股票与股票期权激励计划（以下简称"本次激励计 划"）采取了充分必要的保密措施，同时对激励计划的内幕信息知情人做了必要 登记。根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《深 圳证券交易所上市公司自律监管指南第 1 号——业务办理》等有关法律、法规及 规范性文件的规定，公司向中国证券登记结算有限责任公司深圳分公司（以下简 称"中国结算深圳分公司"）查询了本次激励计划的内幕信息知情人和激励对象 在激励计划(草案)公布日前 6 个月内(2025 年 2 月 28 日至 2025 年 9 月 1 日，以 下简称"自查期间")买卖公司股票的情况，具体情况如下： 一、核查的范围与程序 1、核查对象为本次激励计划的内幕信息 ...

Group 1 - The company *ST Shuangcheng (002693.SZ) currently does not have any innovative drug research and development [1]

Group 1 - The company *ST Shuangcheng (002693.SZ) stated on the interactive platform that there are no plans for restructuring [1]

Group 1 - The company *ST Shuangcheng (002693.SZ) has stated that it currently does not have any innovative drug research and development [1]

Group 1 - The company *ST Shuangcheng (002693.SZ)* confirmed that several of its products have passed the consistency evaluation for generic drugs [2] - The products that have achieved this include Thymosin injection, Somatostatin injection, Octreotide injection, and Bortezomib injection [2]

Core Points - The company *ST Shuangcheng (002693.SZ)* announced a restricted stock and stock option incentive plan for 2025, proposing to grant a total of 20 million stock rights, accounting for 4.82% of the company's total share capital of 414.68975 million shares at the time of the announcement [1] Group 1 - The incentive plan includes a restricted stock grant of 12 million shares, representing 2.89% of the total share capital [1] - The stock option grant proposed in the plan is 8 million shares, which is 1.93% of the total share capital [1] - The grant price for the restricted stock is set at 3.97 yuan per share, while the exercise price for the stock options is 7.93 yuan per share [1] Group 2 - A total of 149 individuals will be granted the incentives, including directors, senior management, middle management, and key technical (business) personnel, excluding independent directors and shareholders holding more than 5% of shares [1] - The validity period for the restricted stock is from the completion of the grant registration until all restrictions are lifted or the stock is repurchased, lasting no more than 48 months [2] - The validity period for the stock options is similarly set from the completion of the grant registration until all options are exercised or canceled, also lasting no more than 48 months [2]

Group 1 - The company is implementing a 2025 restricted stock and stock option incentive plan, which has been reviewed and approved by the Compensation and Assessment Committee [1][2] - The plan aims to enhance the sense of responsibility and mission among the management team and key employees, contributing to the company's sustainable development [2] - The plan's implementation assessment management measures are designed to ensure compliance with relevant laws and regulations, promoting a sound governance structure and value distribution system [2] Group 2 - The list of incentive objects includes directors, senior management, middle management, and key technical (business) personnel, excluding independent directors and major shareholders [3][4] - The eligibility criteria for incentive objects are in accordance with the provisions of the Company Law and Securities Law, ensuring that the selected individuals meet the necessary qualifications [4] - The Compensation and Assessment Committee will disclose the review opinions and public comments on the incentive object list prior to the shareholders' meeting [4]

Core Viewpoint - The company has approved a series of resolutions regarding the 2025 Restricted Stock and Stock Option Incentive Plan, aimed at enhancing corporate governance and motivating key employees for sustainable development [1][2][3]. Group 1: Board Meeting Details - The fifth session of the board's 21st meeting was held on August 30, 2025, with six directors participating and the meeting chaired by Chairman Wang Chengdong [1]. - The meeting complied with relevant laws, regulations, and the company's articles of association [1]. Group 2: Incentive Plan Resolutions - The board approved the draft of the 2025 Restricted Stock and Stock Option Incentive Plan to improve governance and establish a robust incentive mechanism [1][2]. - The plan aims to enhance the sense of responsibility and mission among the management team and core employees for the company's sustainable development [1]. Group 3: Voting Results - The voting results for the incentive plan draft showed 5 votes in favor, 1 abstention, and no opposition [2][5]. - Li Jianming, an associated director, abstained from voting on the proposal [2][5]. Group 4: Authorization for Implementation - The board proposed to authorize itself to handle matters related to the 2025 incentive plan, including determining grant dates and adjusting stock options in case of capital changes [3][4]. - The authorization includes managing the qualifications of participants and handling necessary documentation for granting stock options [4][5]. Group 5: Upcoming Shareholder Meeting - The board has proposed to convene the second extraordinary general meeting of shareholders in 2025 to discuss the incentive plan [5].